Cover Image
Market Research Report
Product code 
1046767

LAMEA Filgrastim Market By Drug Type, By Indication, By Distribution Channel, By Country, Opportunity Analysis and Industry Forecast, 2021 - 2027

Published: | KBV Research | 82 Pages | Delivery time: 1-2 business days

Price

Back to Top
LAMEA Filgrastim Market By Drug Type, By Indication, By Distribution Channel, By Country, Opportunity Analysis and Industry Forecast, 2021 - 2027
Published: November 30, 2021
KBV Research
Content info: 82 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents
  • List of Tables

The Latin America, Middle East and Africa Filgrastim Market would witness market growth of 8.9% CAGR during the forecast period (2021-2027).

Filgrastim is also utilized to boost white blood cells after chemotherapy or radiation therapy for cancer patients and to decrease the chances of infection at the time of stem cell transplantation. Furthermore, filgrastim biosimilar treatment is performed to support the bone marrow to generate more neutrophils (white blood cells) that would help in fighting against the infection in patients who are undergoing chemotherapy for cancer treatment.

In the case of cancer, a patient gets cancer medicines that help them to fight cancer cells, but these medicines can also negatively impact the white blood cells, which fight against infections. Due to this, patients would need filgrastim to help in preventing or reducing the risk of infections at the time, when patients are treated with cancer medicines. By using filgrastim medicine, the bone marrow of a patient would recover soon after bone marrow transplantation, for a procedure that is known as peripheral blood. It also helps in enhancing the survival of cancer patients who were exposed to radiation.

The Middle East region has a relatively stronger healthcare system and the governments across this region have also allotted a huge amount of their budget on building a better healthcare system, which is estimated to create lucrative opportunities for the regional market players. Additionally, the presence and entrance of many market players are also supporting the growth of the regional filgrastim market over the forecast period.

The abundant availability and accessibility of filgrastim in this region are estimated to fuel the regional market growth. Also, the increasing cases of cancer, the growing geriatric population, and the supportive reimbursement policies in the developed nations of the region would augment the overall growth of the regional market. However, the underdeveloped nations of this region may not contribute significantly to the overall growth of the regional filgrastim market in the forecast years.

The Brazil market dominated the LAMEA Filgrastim Market by Country in 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $19.2 million by 2027. The Argentina market is estimated to grow at a CAGR of 9.8% during (2021 - 2027). Additionally, The UAE market would witness a CAGR of 8.4% during (2021 - 2027).

Based on Drug Type, the market is segmented into Biosimilar and Biologic. Based on Indication, the market is segmented into Chemotherapy induced Neutropenia, Chronic Neutropenia and Other Indications. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Amgen, Inc., Pfizer, Inc., Novartis AG, Dr. Reddy's Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Kyowa Kirin Co., Ltd. (Kirin Company), Cadila Healthcare Ltd. (Zydus Cadila), Apotex, Inc., and Toksoz Group

Scope of the Study

Market Segments covered in the Report:

By Drug Type

  • Biosimilar and
  • Biologic

By Indication

  • Chemotherapy induced Neutropenia
  • Chronic Neutropenia and
  • Other Indications

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies and
  • Online Pharmacies

By Country

  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Companies Profiled

  • Abbott Laboratories
  • Amgen, Inc.
  • Pfizer, Inc.
  • Novartis AG
  • Dr. Reddy's Laboratories Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Kyowa Kirin Co., Ltd. (Kirin Company)
  • Cadila Healthcare Ltd. (Zydus Cadila)
  • Apotex, Inc.
  • Toksoz Group

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 LAMEA Filgrastim Market, by Drug Type
    • 1.4.2 LAMEA Filgrastim Market, by Indication
    • 1.4.3 LAMEA Filgrastim Market, by Distribution Channel
    • 1.4.4 LAMEA Filgrastim Market, by Country
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
      • 2.1.1.1 Market Composition and Scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. LAMEA Filgrastim Market by Drug Type

  • 3.1 LAMEA Biosimilar Market by Country
  • 3.2 LAMEA Biologic Market by Country

Chapter 4. LAMEA Filgrastim Market by Indication

  • 4.1 LAMEA Chemotherapy induced Neutropenia Market by Country
  • 4.2 LAMEA Chronic Neutropenia Market by Country
  • 4.3 LAMEA Other Indications Market by Country

Chapter 5. LAMEA Filgrastim Market by Distribution Channel

  • 5.1 LAMEA Hospital Pharmacies Market by Country
  • 5.2 LAMEA Retail Pharmacies Market by Country
  • 5.3 LAMEA Online Pharmacies Market by Country

Chapter 6. LAMEA Filgrastim Market by Country

  • 6.1 Brazil Filgrastim Market
    • 6.1.1 Brazil Filgrastim Market by Drug Type
    • 6.1.2 Brazil Filgrastim Market by Indication
    • 6.1.3 Brazil Filgrastim Market by Distribution Channel
  • 6.2 Argentina Filgrastim Market
    • 6.2.1 Argentina Filgrastim Market by Drug Type
    • 6.2.2 Argentina Filgrastim Market by Indication
    • 6.2.3 Argentina Filgrastim Market by Distribution Channel
  • 6.3 UAE Filgrastim Market
    • 6.3.1 UAE Filgrastim Market by Drug Type
    • 6.3.2 UAE Filgrastim Market by Indication
    • 6.3.3 UAE Filgrastim Market by Distribution Channel
  • 6.4 Saudi Arabia Filgrastim Market
    • 6.4.1 Saudi Arabia Filgrastim Market by Drug Type
    • 6.4.2 Saudi Arabia Filgrastim Market by Indication
    • 6.4.3 Saudi Arabia Filgrastim Market by Distribution Channel
  • 6.5 South Africa Filgrastim Market
    • 6.5.1 South Africa Filgrastim Market by Drug Type
    • 6.5.2 South Africa Filgrastim Market by Indication
    • 6.5.3 South Africa Filgrastim Market by Distribution Channel
  • 6.6 Nigeria Filgrastim Market
    • 6.6.1 Nigeria Filgrastim Market by Drug Type
    • 6.6.2 Nigeria Filgrastim Market by Indication
    • 6.6.3 Nigeria Filgrastim Market by Distribution Channel
  • 6.7 Rest of LAMEA Filgrastim Market
    • 6.7.1 Rest of LAMEA Filgrastim Market by Drug Type
    • 6.7.2 Rest of LAMEA Filgrastim Market by Indication
    • 6.7.3 Rest of LAMEA Filgrastim Market by Distribution Channel

Chapter 7. Company Profiles

  • 7.1 Abbott Laboratories
    • 7.1.1 Company Overview
    • 7.1.2 Financial Analysis
    • 7.1.3 Segmental and Regional Analysis
    • 7.1.4 Research & Development Expense
  • 7.2 Amgen, Inc.
    • 7.2.1 Company Overview
    • 7.2.2 Financial Analysis
    • 7.2.3 Regional Analysis
    • 7.2.4 Research & Development Expenses
  • 7.3 Pfizer, Inc.
    • 7.3.1 Company Overview
    • 7.3.2 Financial Analysis
    • 7.3.3 Regional Analysis
    • 7.3.4 Research & Development Expense
    • 7.3.5 Recent strategies and developments:
      • 7.3.5.1 Approvals and Trials:
  • 7.4 Novartis AG
    • 7.4.1 Company Overview
    • 7.4.2 Financial Analysis
    • 7.4.3 Segmental and Regional Analysis
    • 7.4.4 Research & Development Expense
    • 7.4.5 Recent strategies and developments:
      • 7.4.5.1 Product Launches and Product Expansions:
  • 7.5 Dr. Reddy's Laboratories Ltd.
    • 7.5.1 Company Overview
    • 7.5.2 Financial Analysis
    • 7.5.3 Segmental and Regional Analysis
    • 7.5.4 Research & Development Expense
    • 7.5.5 Recent strategies and developments:
      • 7.5.5.1 Partnerships, Collaborations, and Agreements:
      • 7.5.5.2 Product Launches and Product Expansions:
  • 7.6 Teva Pharmaceutical Industries Ltd.
    • 7.6.1 Company Overview
    • 7.6.2 Financial Analysis
    • 7.6.3 Regional Analysis
    • 7.6.4 Research & Development Expenses
    • 7.6.5 Recent strategies and developments:
      • 7.6.5.1 Approvals and Trials:
  • 7.7 Kyowa Kirin Co., Ltd. (Kirin Company)
    • 7.7.1 Company Overview
    • 7.7.2 Financial Analysis
    • 7.7.3 Regional Analysis
    • 7.7.4 Research & Development Expense
    • 7.7.5 Recent strategies and developments:
      • 7.7.5.1 Partnerships, Collaborations, and Agreements:
  • 7.8 Cadila Healthcare Ltd. (Zydus Cadila)
    • 7.8.1 Company Overview
    • 7.8.2 Financial Analysis
    • 7.8.3 Segmental and Regional Analysis
    • 7.8.4 Research & Development Expense
  • 7.9 Apotex, Inc.
    • 7.9.1 Company Overview
    • 7.9.2 Recent strategies and developments:
      • 7.9.2.1 Product Launches and Product Expansions:
  • 7.10 Toksoz Group
    • 7.10.1 Company Overview

LIST OF TABLES

  • TABLE 1 LAMEA Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 2 LAMEA Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 3 LAMEA Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 4 LAMEA Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 5 LAMEA Biosimilar Market by Country, 2017 - 2020, USD Million
  • TABLE 6 LAMEA Biosimilar Market by Country, 2021 - 2027, USD Million
  • TABLE 7 LAMEA Biologic Market by Country, 2017 - 2020, USD Million
  • TABLE 8 LAMEA Biologic Market by Country, 2021 - 2027, USD Million
  • TABLE 9 LAMEA Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 10 LAMEA Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 11 LAMEA Chemotherapy induced Neutropenia Market by Country, 2017 - 2020, USD Million
  • TABLE 12 LAMEA Chemotherapy induced Neutropenia Market by Country, 2021 - 2027, USD Million
  • TABLE 13 LAMEA Chronic Neutropenia Market by Country, 2017 - 2020, USD Million
  • TABLE 14 LAMEA Chronic Neutropenia Market by Country, 2021 - 2027, USD Million
  • TABLE 15 LAMEA Other Indications Market by Country, 2017 - 2020, USD Million
  • TABLE 16 LAMEA Other Indications Market by Country, 2021 - 2027, USD Million
  • TABLE 17 LAMEA Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 18 LAMEA Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 19 LAMEA Hospital Pharmacies Market by Country, 2017 - 2020, USD Million
  • TABLE 20 LAMEA Hospital Pharmacies Market by Country, 2021 - 2027, USD Million
  • TABLE 21 LAMEA Retail Pharmacies Market by Country, 2017 - 2020, USD Million
  • TABLE 22 LAMEA Retail Pharmacies Market by Country, 2021 - 2027, USD Million
  • TABLE 23 LAMEA Online Pharmacies Market by Country, 2017 - 2020, USD Million
  • TABLE 24 LAMEA Online Pharmacies Market by Country, 2021 - 2027, USD Million
  • TABLE 25 LAMEA Filgrastim Market by Country, 2017 - 2020, USD Million
  • TABLE 26 LAMEA Filgrastim Market by Country, 2021 - 2027, USD Million
  • TABLE 27 Brazil Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 28 Brazil Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 29 Brazil Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 30 Brazil Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 31 Brazil Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 32 Brazil Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 33 Brazil Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 34 Brazil Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 35 Argentina Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 36 Argentina Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 37 Argentina Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 38 Argentina Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 39 Argentina Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 40 Argentina Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 41 Argentina Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 42 Argentina Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 43 UAE Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 44 UAE Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 45 UAE Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 46 UAE Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 47 UAE Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 48 UAE Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 49 UAE Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 50 UAE Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 51 Saudi Arabia Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 52 Saudi Arabia Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 53 Saudi Arabia Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 54 Saudi Arabia Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 55 Saudi Arabia Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 56 Saudi Arabia Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 57 Saudi Arabia Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 58 Saudi Arabia Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 59 South Africa Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 60 South Africa Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 61 South Africa Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 62 South Africa Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 63 South Africa Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 64 South Africa Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 65 South Africa Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 66 South Africa Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 67 Nigeria Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 68 Nigeria Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 69 Nigeria Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 70 Nigeria Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 71 Nigeria Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 72 Nigeria Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 73 Nigeria Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 74 Nigeria Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 75 Rest of LAMEA Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 76 Rest of LAMEA Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 77 Rest of LAMEA Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 78 Rest of LAMEA Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 79 Rest of LAMEA Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 80 Rest of LAMEA Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 81 Rest of LAMEA Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 82 Rest of LAMEA Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 83 Key Information - Abbott Laboratories
  • TABLE 84 Key Information - Amgen, Inc.
  • TABLE 85 Key Information - Pfizer, Inc.
  • TABLE 86 Key Information - Novartis AG
  • TABLE 87 key information - Dr. Reddy's Laboratories Ltd.
  • TABLE 88 Key Information - Teva Pharmaceuticals Industries Ltd.
  • TABLE 89 Key Information - Kyowa Kirin Co., Ltd.
  • TABLE 90 Key Information - Cadila Healthcare Ltd.
  • TABLE 91 Key Information - Apotex, Inc.
  • TABLE 92 Key Information - Toksoz Group

List of Figures

  • FIG 1 Methodology for the research